CXCL12 and plasma cell myeloma: However, a study by Kim et al (49) revealed that CXCL12 did not affect the proliferation of CXCR4+ myeloma cells, and AMD3100 has dual effects, initially enhancing and subsequently inhibiting myeloma cell proliferation.